? RECRUITMENT, INTERVENTION AND SURVEY SHARED RESOURCE (RISSR) The RISSR was established in 2003, as the Behavioral Measurement Shared Resource (BMSR), to provide a mechanism for supporting behavioral, epidemiological and clinical research within the broader research goals of the OSUCCC. Renamed in 2019, the RISSR provides essential services to support non-interventional studies (observational, epidemiologic) as well as non-therapeutic intervention studies. Thus, the RISSR is a niche service for population scientists in CC and MCC providing efficient and high quality services for investigators to conduct population science research. RISSR also works with the BSSR to support the Total Cancer Care (TCC) project accruals, and translational research involving human data collection and interventions for all 5 research programs. For the next funding period, the RISSR specific aims are to: 1) provide expertise in research design, the selection and/or development of surveys and study measures, including patient-reported outcomes; 2) assist investigators with participant recruitment, accrual goals, and retention to ensure the inclusion of research participants that are representative of the target population(s); and 3) provide investigators with expertise and services in the collection and management of quantitative and qualitative research data, and population-based data retrieval for grant applications and registry studies. Collected data are managed for seamless transfer to the BSR for data analysis. Over the current funding cycle, the major changes to the RISSR were greater adoption of electronic data collection for the majority of OSUCCC studies, using text messaging with participants for more flexible communication, data collection and study conduct; increased use of mobile health interventions; and providing support for more program projects and large multi-heath center/ multi-state research projects. During the current funding cycle, RISSR has supported 35 principal investigators (54% OSUCCC members) and contributed to 71 publications (1 >10 impact factor) and 9 NCI grants including 1 K01, 1 K07, 1 K12, 1 P01, 2 P50s, 2 R01s, and 1 R37. The RISSR will directly support the OSUCCC priority for immune-oncology and cancer prevention and control. The RISSR will expand its staff, instrumentation and services before capacity is reached. In the next funding cycle, the RISSR will: 1) further develop and customize survey and data collection methods; 2) expand and support participant recruitment registries for rapid accrual for interventional and epidemiological studies; 3) expand the provision of smart phones to study participants to reduce disparities in participant recruitment and participation; and 4) develop greater linkages with the BISR to share computer platforms and expertise related to clinical informatics, eHealth interventions using the electronic health record, and health services research. The RISSR will also work with the BSR and BISR as part of the Biomedical Informatics Coordinating Center (BMICC) Working Group to establish national data coordinating centers at the OSUCCC on cancer-related topics. The annual budget of the RISSR is $1,631,722, yet the CCSG request is $92,102 (5.6%) reflecting strong institutional support and a robust chargeback system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090018
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932
Wang, Xinmei; Kwak, Kwang Joo; Yang, Zhaogang et al. (2018) Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One 13:e0198552
Callahan, Catherine L; Bonner, Matthew R; Nie, Jing et al. (2018) Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. Environ Res 161:418-424
Gopalakrishnan, Bhavani; Cheney, Carolyn; Mani, Rajeswaran et al. (2018) Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget 9:9706-9713
Hankey, William; Frankel, Wendy L; Groden, Joanna (2018) Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 37:159-172
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Stover, Daniel G; Parsons, Heather A; Ha, Gavin et al. (2018) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 36:543-553
Jacobsen, Paul B; DeRosa, Antonio P; Henderson, Tara O et al. (2018) Systematic Review of the Impact of Cancer Survivorship Care Plans on Health Outcomes and Health Care Delivery. J Clin Oncol 36:2088-2100

Showing the most recent 10 out of 2602 publications